National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Myelodysplastic/Myeloproliferative Diseases Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 08/01/2008



General Information About Myelodysplastic/Myeloproliferative Diseases






Chronic Myelomonocytic Leukemia






Juvenile Myelomonocytic Leukemia






Atypical Chronic Myelogenous Leukemia






Myelodysplastic/Myeloproliferative Disease, Unclassifiable






Stages of Myelodysplastic/Myeloproliferative Diseases






Treatment Option Overview






Treatment Options for Myelodysplastic/Myeloproliferative Diseases






To Learn More About Myelodysplastic/Myeloproliferative Diseases






Get More Information From NCI






Changes to This Summary (08/01/2008)






About PDQ



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Atypical Chronic Myelogenous Leukemia

Key Points for This Section


Atypical chronic myelogenous leukemia is a disease in which too many granulocytes (immature white blood cells) are made in the bone marrow.

In atypical chronic myelogenous leukemia (aCML), the body tells too many blood stem cells to develop into a type of white blood cell called granulocytes. Some of these blood stem cells never become mature white blood cells. These immature white blood cells are called blasts. Over time, the granulocytes and blasts crowd out the red blood cells and platelets in the bone marrow.

The leukemia cells in aCML and chronic myelogenous leukemia (CML) look alike under a microscope. However, in aCML a certain chromosome change, called the "Philadelphia chromosome" is not present.

Possible signs of atypical chronic myelogenous leukemia include easy bruising or bleeding and feeling tired and weak.

These and other symptoms may be caused by aCML. Other conditions may cause the same symptoms. A doctor should be consulted if any of the following problems occur:

  • Shortness of breath.
  • Pale skin.
  • Feeling very tired and weak.
  • Easy bruising or bleeding.
  • Petechiae (flat, pinpoint spots under the skin caused by bleeding).
  • Pain or a feeling of fullness below the ribs on the left side.

Certain factors affect prognosis (chance of recovery).

The prognosis (chance of recovery) for aCML depends on the number of red blood cells and platelets in the blood.

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov